Omega Flex, Inc. — Form 10-Q Summary
Reporting period: Quarter and six months ended June 30, 2023; filed August 4, 2023. The unaudited statements are prepared under U.S. GAAP. Omega Flex manufactures and sells flexible metal hose, fittings, and accessories through facilities in the United States and United Kingdom. The company reports one operating segment.
Financial Performance and Position
| Metric | Q2 2023 | Q2 2022 | Six months 2023 | Six months 2022 |
|---|---|---|---|---|
| Net sales | $25.835 million | $31.748 million | $55.822 million | $63.041 million |
| Gross profit | $15.800 million | $20.793 million | $34.428 million | $39.908 million |
| Gross margin | 61.2% | 65.5% | 61.7% | 63.3% |
| Operating profit | $5.521 million | $7.342 million | $12.827 million | $14.708 million |
| Operating margin | 21.4% | 23.1% | 23.0% | 23.3% |
| Net income attributable to Omega Flex | $4.556 million | $5.450 million | $10.298 million | $10.901 million |
| Diluted EPS | $0.45 | $0.54 | $1.02 | $1.08 |
- Q2 sales declined 18.6%; six-month sales declined 11.5%. Management attributed the decrease mainly to lower unit volumes and a suppressed market, including fewer housing starts.
- Q2 gross profit declined 24.0%, and six-month gross profit declined 13.7%. Gross-margin compression reflected lower production and factory overhead absorption, pricing actions taken in the prior year, and higher excess-inventory provisions related to new corrugated medical tubing products.
- Q2 operating profit declined 24.8%; six-month operating profit declined 12.8%. Selling, general and administrative, and engineering expenses decreased, partly offsetting the gross-profit decline.
- Interest income increased to $396,000 in Q2 and $677,000 for the six months, compared with $11,000 and $20,000, respectively, due primarily to higher interest rates.
- Cash flow from operating activities was $9.457 million for the six months, compared with $873,000 in the prior-year period. Capital expenditures were $817,000, and dividends paid were $6.461 million.
- Cash and cash equivalents were $39.875 million at June 30, 2023, compared with $37.703 million at December 31, 2022. Total assets were $94.376 million and total shareholders’ equity was $75.092 million.
- Accounts receivable decreased to $14.264 million from $17.503 million at year-end, while inventories were $17.375 million versus $17.764 million. Inventory reserves increased to $770,000 from $571,000.
- The company had no outstanding borrowings at June 30, 2023 and was in compliance with debt covenants. Operating lease liabilities totaled $3.147 million, including $426,000 current.
- Regular dividends declared were $0.33 per share in June 2023, compared with $0.32 per share in June 2022. Six-month dividends declared increased to $6.561 million from $6.258 million.
Material Changes and Unusual Items
- General and administrative expense decreased 35.2% in Q2 and 20.3% for the six months, primarily because the prior-year periods included higher product-liability reserves and incentive compensation. Two legal and product-liability matters were resolved through settlement and paid during the first quarter of 2023.
- Product-liability accruals decreased to $429,000 at June 30, 2023 from $3.848 million at December 31, 2022. The company continues to face claims relating primarily to alleged lightning or electrical damage involving its flexible gas-piping products.
- The company recorded $683,000 of inventory-reserve expense during the six months, and $500,000 of inventory related to new corrugated medical tubing products was classified as expected to be used beyond the next twelve months.
- Stock-based compensation expense was $429,000 for the six months, compared with $132,000 in the prior-year period. The company had 5,840 nonvested and unmatured phantom stock units outstanding at June 30, 2023.
- On July 3, 2023, after the reporting date, Omega Flex entered into a new unsecured revolving credit facility with Santander Bank for up to $15.0 million, including a $1.0 million letter-of-credit sublimit, expiring June 1, 2028. Borrowings bear interest at Term SOFR or Prime plus applicable margins.
Liquidity, Outlook, and Risks
Management stated that existing cash, operating cash generation, and the available borrowing capacity are expected to satisfy anticipated cash needs for at least the next twelve months. Future capital requirements will depend on revenue growth, expansion, acquisitions, and capacity investments. The filing does not provide formal revenue or earnings guidance.
- Key operating risks include continued weakness in housing and construction markets, lower production volumes, excess inventory related to the medical-tubing product line, customer concentration, and dependence on North American sales.
- One customer represented more than 10% of accounts receivable at June 30, 2023 and more than 10% of six-month sales; the filing does not identify the customer.
- Open claims had estimated aggregate exposure of approximately $3.808 million within applicable insurance deductibles or self-insured retentions. Management cannot predict the ultimate liability, if any.
- The new credit facility has variable-rate exposure to SOFR or Prime. Although no borrowings were outstanding, higher or more volatile rates could increase future borrowing costs and affect liquidity and earnings.
- Management concluded that disclosure controls were effective as of June 30, 2023, and reported no material changes to internal control over financial reporting during the quarter.
Investor Verification Checklist
- Verify whether housing-start and broader construction-market weakness continues to pressure unit volumes and sales.
- Monitor gross margin for recovery or further deterioration, particularly the effects of CMT inventory reserves, production absorption, pricing, and material costs.
- Assess adoption, sales growth, and inventory utilization for the MediTrac/CMT product line.
- Review subsequent filings for borrowings, interest costs, covenant compliance, and availability under the July 2023 Santander facility.
- Track developments in product-liability claims, insurance retentions, legal accruals, and potential cash settlements.
- Evaluate customer concentration and the effect of dividends on cash balances and retained earnings.